China’s Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has acquired a 19.96% stake in ND Pharm, becoming the firm’s second-largest shareholder. Financial terms were undisclosed. The move positions Aidea to leverage ND Pharm’s market-leading urokinase products, complementing its existing human protein portfolio.
ND Pharm’s Market Position
ND Pharm markets injectable urokinase and small molecule heparin sodium APIs. Its urokinase products hold a significant domestic market share. In 2021, China’s human urokinase preparations market surged to RMB857 million ($126.9 million), doubling from RMB414 million ($61.3 million) in 2020. ND Pharm accounted for 41.36% of sales over the past three years, solidifying its status as China’s top urokinase manufacturer.
Aidea’s Strategic Expansion
Aidea Pharma, a human protein specialist, currently markets crude urokinase, ulinastatin, and kallidinogenase. The ND Pharm stake enhances its thrombolytic therapy offerings, targeting cardiovascular, cerebrovascular, and thrombolysis applications, including hemodialysis and cerebral infarction treatment.-Fineline Info & Tech
